Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202054 | 0.81 | NOTUM (0.37) | NISCHNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL1973038 | 0.80 | MAPK14 (0.36) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL1980545 | 0.80 | ALDH1A1 (0.38) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL435455 | 0.80 | CYP1A2 (0.38) | KMT2ANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL11240403 | 0.79 | MAPT (0.46) | KMT2ANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL10562349 | 0.79 | NPC1 (0.38) | NISCHMEN1KMT2ANPC1RAB9A | |
| SCHEMBL8081622 | 0.79 | NISCH (0.38) | NISCHNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL1967426 | 0.79 | CLK4 (0.56) | NPC1RAB9AALDH1A1KDM4EGAA | |
| SCHEMBL5056973 | 0.79 | ACHE (0.42) | NISCHNPC1RAB9AACHEHPGD | |
| SCHEMBL2397171 | 0.79 | MAPT (0.42) | NPC1RAB9AALDH1A1KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104837832-B | GDF-8 inhibitors | 里格尔药品股份有限公司 | 2019-04-26 | — | — | CN | claimed |
| CN-104837832-A | GDF-8 inhibitors | RIGEL PHARMACEUTICALS INC | 2015-08-12 | — | — | CN | claimed |
| CN-106536507-B | 2, 3-disubstituted pyridine compounds as TGF- β inhibitors and methods of use thereof | 里格尔药品股份有限公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-104837832-B | GDF-8 inhibitors | 里格尔药品股份有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-106536507-A | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | 里格尔药品股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-104837832-A | GDF-8 inhibitors | RIGEL PHARMACEUTICALS INC | 2015-08-12 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1133036-A | 2-oximino-2-pyridyl acetic acid derivatives as anti-parasitic agents (fungicides) | BAYER AG (DE) | 1996-10-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NISCH 2425/4885MEN1 3295/4885KMT2A 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.